{"id":"NCT04475081","sponsor":"Louisiana State University Health Sciences Center in New Orleans","briefTitle":"Use of a Live Attenuated Vaccine as an Immune-based Preventive Against COVID-19-associated Sepsis","officialTitle":"Use of a Live Attenuated Vaccine Repurposed as an Innate Immune-based Preventive Against COVID-19-associated Sepsis/Inflammation","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-09-22","primaryCompletion":"2022-05-15","completion":"2022-05-15","firstPosted":"2020-07-17","resultsPosted":"2024-11-26","lastUpdate":"2024-11-26"},"enrollment":50,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"SINGLE","primaryPurpose":"PREVENTION"},"conditions":["Sepsis Syndrome"],"interventions":[{"type":"BIOLOGICAL","name":"MMR vaccine","otherNames":[]}],"arms":[{"label":"MMR vaccination","type":"EXPERIMENTAL"},{"label":"Placebo control","type":"PLACEBO_COMPARATOR"}],"summary":"The objective of this randomized clinical trial is to test whether administration of live attenuated MMR vaccine (measles mumps rubella; Merck) to eligible adults at highest risk for contracting COVID-19 (healthcare workers, first responders), can induce non-specific trained innate immune leukocytes that can prevent/dampen pathological inflammation and sepsis associated with COVID-19-infection, if exposed.","primaryOutcome":{"measure":"Induction of MDSCs","timeFrame":"30 days post vaccination","effectByArm":[{"arm":"MMR Vaccination","deltaMin":0.19,"sd":0.19},{"arm":"Placebo Control","deltaMin":0.11,"sd":0.17}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":4,"exclusionCount":13},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["32561657","37153751"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":19},"commonTop":[]}}